Compare Ascendis Pharma A/S (ASND) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Tyson Foods, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Tyson Foods, Inc. trades at $58.37 (market cap $20.36B). The key difference: Ascendis Pharma A/S and Tyson Foods, Inc. are close in size by market cap, and Tyson Foods, Inc. pays a 3.53% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TSN | |
|---|---|---|
Market Cap | $17.74B | $20.36B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $68.75 |
52-Week Low | $163.32 | $50.72 |
Enterprise Value | $18.11B | $27.95B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Tyson Foods (TSN) trades at $57.83, showing modest daily gains. The stock presents mixed signals with a bearish technical outlook but strong analyst support (50% buy ratings) and a consensus price target of $69.75. Recent earnings have beaten expectations in two of the last three quarters, while fundamentals show stable revenue near $54.4 billion but thin net margins of 0.81%. The company maintains dividend payments and is focusing on prepared foods growth.
The investment case balances value metrics like low P/S of 0.37 against profitability challenges. Upside potential exists if margin improvements materialize, but risks include volatile input costs and competitive pressures. The stock appears undervalued relative to analyst targets, suggesting cautious optimism for patient investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
